Lynx Q1 Revenues Up Slightly, Losses Widen | GenomeWeb

NEW YORK, April 25  - Despite a flurry of new collaborations with users of its microbead technology, Lynx Therapeutics reported Wednesday nearly flat first-quarter revenues.

Lynx’s revenues increased slightly to $3.4 million, from $3.0 million for the first quarter of 2000, stemming from service and access fees to Lynx’s technology. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.